

# Gut epithelial barrier and systemic inflammation during chronic HIV infection

Ma Somsouk<sup>a</sup>, Jacob D. Estes<sup>b</sup>, Claire Deleage<sup>b</sup>, Richard M. Dunham<sup>c</sup>,  
Rebecca Albright<sup>c</sup>, John M. Inadomi<sup>d</sup>, Jeffrey N. Martin<sup>e</sup>,  
Steven G. Deeks<sup>f</sup>, Joseph M. McCune<sup>c</sup> and Peter W. Hunt<sup>f</sup>

**Objective:** Microbial translocation and innate immune action characterize HIV infection. Continued gut mucosal dysfunction during treatment and its relationship to CD4<sup>+</sup> T-cell recovery has not been well described.

**Design:** A cross-sectional study was performed of antiretroviral therapy (ART)-suppressed (immunologic responders with CD4<sup>+</sup> > 500 cells/ $\mu$ l and immunologic non-responders with CD4<sup>+</sup> < 350 cells/ $\mu$ l), untreated HIV-infected, and seronegative participants consenting to gut biopsies and a blood draw.

**Methods:** Neutrophil infiltration as a surrogate response to epithelial breach, colorectal epithelial proliferation as a measure of repair, and mucosal apoptosis by immunohistochemistry were determined in gut biopsies. Plasma markers of monocyte activation (sCD14), immune activation (interleukin-6), and indoleamine 2,3-dioxygenase-1 activity (plasma kynurenine/tryptophanratio) were concurrently measured.

**Results:** Each HIV-infected group had greater neutrophil infiltration than controls. Similarly, untreated HIV-infected participants and ART-suppressed immunologic responders had increased epithelial proliferation compared with controls, but immunologic nonresponders had no appreciable increase in epithelial proliferation despite elevated neutrophil infiltration. The CD4<sup>+</sup> T-cell count was positively correlated with epithelial proliferation and was modestly negatively correlated with neutrophil infiltration in ART-suppressed patients. Epithelial proliferation was inversely correlated with mucosal apoptosis, and apoptosis was linked to plasma sCD14 and modestly to kynurenine/tryptophan ratio.

**Conclusions:** Neutrophil infiltration and mucosal apoptosis remain abnormally high despite ART. Epithelial proliferation increases in HIV, but may be impaired in immunologic nonresponders. Whether mucosal apoptosis is a cause or consequence of epithelial proliferative defects is unclear, but appears to be associated with systemic inflammation. The impact of ART and interventions targeting the gut epithelial barrier in treated HIV infection warrant further investigation.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

*AIDS* 2015, **29**:43–51

**Keywords:** epithelial proliferation, HIV, immune activation, inflammation, microbial translocation

---

<sup>a</sup>Division of Gastroenterology, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, <sup>b</sup>AIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, <sup>c</sup>Division of Experimental Medicine, Department of Medicine, UCSF, San Francisco, California, <sup>d</sup>Division of Gastroenterology, Department of Medicine, University of Washington, Washington, <sup>e</sup>Department of Epidemiology and Biostatistics, and <sup>f</sup>HIV/AIDS Division, Department of Medicine, UCSF, San Francisco, California, USA.

Correspondence to Ma Somsouk, MD, MAS, 1001 Potrero Avenue, San Francisco, CA 94110, USA.

Tel: +1 415 206 6480; fax: +1 415 641 0745; e-mail: somsoukma@medsfgh.ucsf.edu

Received: 13 August 2014; revised: 29 September 2014; accepted: 9 October 2014.

DOI:10.1097/QAD.0000000000000511

## Background

Despite dramatic improvements in life expectancy in the modern antiretroviral therapy (ART) era, HIV-infected individuals, particularly those who start ART at the later stages of the disease, still have shorter life expectancy than the general population [1–4]. Abnormally high immune activation and inflammation follow HIV infection, persist during ART, and predict non-AIDS-associated morbidities and death [5–10].

Increased immune activation has been linked to microbial translocation during both untreated and treated HIV infection [11–14]. Whereas the levels of microbial translocation [e.g. as measured by plasma lipopolysaccharide (LPS)] and innate immune activation decrease during suppressive ART, they remain persistently elevated and may contribute to the inflammatory state [6,15]. Observations in pathogenic simian immunodeficiency virus (SIV) infection argue that intestinal barrier dysfunction is a source of microbial translocation due to extensive neutrophil infiltration, epithelial proliferative response, and persistent gut mucosal apoptosis [16–18]. Treatment of HIV infection decreases epithelial apoptosis in the duodenal tissue, but apoptosis remains elevated compared to uninfected controls [19,20]. Residual barrier dysfunction as measured by soluble markers predict increased mortality during treated HIV infection [21], but direct measurements of the gut mucosa across a spectrum of CD4<sup>+</sup> cell count has not been reported. Given these observations, we sought to explore if epithelial breach persists in the gut compartment of untreated and treated HIV-infected individuals and their impact on systemic immune activation. Specifically, our objective was to characterize neutrophil infiltration as a surrogate for epithelial breach, epithelial repair by measuring crypt proliferation, and mucosal apoptosis, and how they relate to CD4<sup>+</sup> T-cell recovery and systemic immune activation.

## Methods

### Patient recruitment and sample collection

Since 2006, HIV-infected individuals and controls have been recruited and consented from the SCOPE cohort at University of California, San Francisco (UCSF), for sigmoidoscopy and collecting relevant gastrointestinal biopsy samples for research purposes. The SCOPE cohort is an ongoing longitudinal study of over 1500 HIV-infected and uninfected adults based at the San Francisco General Hospital. SCOPE was designed to characterize the natural history of both antiretroviral-treated and untreated HIV disease with standardized interviews and specimen collection. Participants come from across the Bay Area. Using this cohort, 73 HIV-negative controls, HIV-viremic untreated, and individuals suppressed with ART with archived gut biopsies were selected. The ART

group included HIV-infected patients maintaining undetectable viral loads (<40 copies/ml) on stable ART for at least 1 year and were subdivided by the extent of peripheral blood CD4<sup>+</sup> T-cell recovery: immunologic nonresponders (INR) (CD4<sup>+</sup> T-cell count <350 cells/ $\mu$ l) and immunologic responders (IR) (CD4<sup>+</sup> T-cell count > 500 cells/ $\mu$ l).

Prior to their procedure, the study participants underwent a blood draw and received a Fleet enema, and rectosigmoid biopsies (each ~3 mm in diameter) were then obtained between 10 and 20 cm from the anus using jumbo forceps. Four biopsies were formalin-fixed and paraffin-embedded (FFPE) for immunohistochemistry. The available FFPE colonic tissue blocks and the plasma samples were the basis of this study.

### Immunohistochemistry and quantitative image analysis

To minimize bias, investigators quantifying mucosal measurements were blinded to group status. Immunohistochemistry was performed as previously described [22]. Antibodies used in this study were rabbit monoclonal cleaved caspase-3 (Cell Signaling Technology Inc., Danvers, Massachusetts, USA; clone 5A1E), rabbit monoclonal anti-Ki67 [1 : 100; clone SP6; Labvision/Thermo Scientific (Thermo Fisher Scientific, Fremont, California, USA)] and rabbit polyclonal antimyeloperoxidase (1 : 2000; Dako Inc., Carpinteria, California, USA). All stained slides were scanned at a high magnification ( $\times$ 200) using the ScanScope CS System (Aperio ePathology, Leica Microsystems Inc., Buffalo Grove, Illinois, USA), yielding high-resolution data from the entire tissue section. Representative regions of interest (ROIs; 250–500  $\mu$ m<sup>2</sup>) were identified and high-resolution images extracted from these whole-tissue scans. The percentage area of the lamina propria that stained for cleaved caspase-3 (including colonic epithelial cells) or myeloperoxidase was quantified using Photoshop CS5 and Fovea tools. Colonic crypt epithelial cell proliferation was measured using the Aperio Scanscope ruler tool on coronally aligned colonic crypts (in which the bases, middle portions, and tops were in the same focal plane). From the crypt base, the extent of epithelial cells undergoing proliferation was divided by the entire length of the crypt and the median proportion of crypt length for each patient staining positive for Ki67 is reported. Not all stains were performed on all samples due to the absence of intestinal epithelial crypts aligned coronally or tissue blocks no longer available for sectioning.

Cleaved cytokeratin-18 stain, specific for epithelial apoptosis and used in a nonhuman primate study [17], was also assayed in this study. However, several distinct challenges rendered the marker too variable for this study. First, due to the small biopsies and the cleaved cytokeratin-18 stains primarily colonic enterocytes at the crypt surface, tissue orientation was variably aligned

to preclude sufficient visualization of intact crypt structures. Secondly, due to the lower extent of enterocyte apoptosis as compared to observations in acute SIV-infected macaques, there was considerable variability in detection of cleaved cytokeratin-18. Finally, because we utilized biopsies from the SCOPE cohort that spanned sample collections over 5 years, we found that the cytokeratin-18 staining was not robust in older archived tissue specimens with variable background noise. Therefore, although tested, we were concerned about the interpretability of the cytokeratin-18 marker.

### Plasma inflammatory marker measurements

Cryopreserved plasma was thawed and batched for assessment of biomarkers of the gut epithelial barrier function, inflammation, monocyte activation, and indoleamine 2,3-dioxygenase-1 (IDO-1) activity. ELISA, using commercially available kits, was performed according to the manufacturer's instructions in duplicates: interleukin (IL)-6, sCD14, intestinal fatty acid-binding protein (I-FABP2) (all from R&D Systems, Inc., Minnesota, USA), and D-dimer (Diagnostica Stago, Inc., New Jersey, USA). Concentrations of kynurenine and tryptophan were quantitated in plasma by liquid chromatography-tandem mass spectrometry, as previously described, as a marker of IDO-1 activity [23].

### Statistical analysis

Pair-wise comparisons between groups in continuous variables were assessed with Wilcoxon rank-sum tests. Correlations were examined using Spearman's rank correlation. These analyses were performed using Stata 11.0 (StataCorp LP, College Station, Texas, USA) and GraphPad Prism v5.0b (GraphPad Software, Inc., La Jolla, California, USA). Adjusted differences were compared between groups with multivariable linear regression, transforming variables as appropriate to satisfy model assumptions.

## Results

### Patient characteristics

A total of 15 viremic-untreated, 24 ART-suppressed immunologic nonresponders, 15 ART-suppressed immunologic responders, and 19 HIV-uninfected controls were studied (Table 1). The median age was above 44 years and

was not significantly different between the groups. All but three participants were men (two viremic, one immunologic responder). Among the viremic patients, the median viral load was 4.6 log<sub>10</sub> copies/ml, and the median CD4<sup>+</sup> T-cell count was 510 cells/μl, reflecting relatively early-stage disease. Among the ART-suppressed participants, median CD4<sup>+</sup> T-cell counts reflected our sampling strategy: 628 cells/μl in immunologic responders and 229 cells/μl in nonresponders.

### Neutrophil infiltration persists despite antiretroviral therapy

All HIV-infected groups had higher levels of neutrophil infiltration compared to HIV-uninfected controls ( $P \leq 0.04$  for all groups; Figs. 1 and 2a), with the highest levels in immunologic nonresponders (median 0.7 vs. 0.3%;  $P = 0.001$ ) (Table 2). Higher neutrophil infiltration tended to associate with lower CD4<sup>+</sup> T-cell counts ( $\rho = -0.31$ ,  $P = 0.06$ ). This suggests that epithelial breach and translocation of microbes persist despite ART and may be linked to the degree of immune restoration.


### Limited epithelial proliferation among individuals with incomplete immunologic recovery

Given that increased neutrophil infiltration has been associated with epithelial barrier damage and breach in the SIV macaque model [16], and shown here to be increased with HIV infection, we hypothesized that epithelial proliferation would increase as a host compensatory mechanism to repair gastrointestinal epithelial damage. Indeed, similar to observations in SIV-infected rhesus macaques [17], HIV-infected viremic participants had higher median levels of epithelial cell proliferation (defined as the proportion of crypt length staining positive for Ki67) than the HIV-uninfected controls (55 vs. 40%;  $P = 0.01$ ), as did immunologic responders (52%,  $P = 0.02$ ; Fig. 2b and Table 2). However, immunologic nonresponders – despite having abnormally high neutrophil infiltration – had similar levels of epithelial proliferation to HIV-uninfected controls ( $P = 0.57$ ) and significantly lower levels than viremic patients ( $P = 0.02$ ) and immunologic responders ( $P = 0.04$ ). Moreover, among ART-suppressed individuals, crypt epithelial proliferation was positively correlated with CD4<sup>+</sup> T-cell count ( $\rho = 0.43$ ,  $P = 0.02$ ; Fig. 3a) and modestly correlated with the nadir CD4<sup>+</sup> T-cell count ( $\rho = 0.32$ ,  $P = 0.05$ ; not shown).

**Table 1. Baseline characteristics of the study participants.**

	HIV-negative median (IQR) (n = 19)	HIV+ untreated median (IQR) (n = 15)	ART+ CD4 <sup>+</sup> >500 median (IQR) (n = 15)	ART+ CD4 <sup>+</sup> <350 median (IQR) (n = 24)
Age	47 (37–55)	44 (34–51)	49 (47–55)	47 (43–52)
Men [n (%)]	16 (100)	13 (86)	14 (93)	24 (100)
CD4 <sup>+</sup> T-cell count (cells/μl)	–	510 (347–714)	628 (532–1011)	229 (155–279)
CD4 <sup>+</sup> T-cell nadir (cells/μl)	–	400 (320–500)	105 (49–311)	21 (7–56)
Duration of ART (years)	–	–	9.8 (4.4–10.7)	11.3 (7.8–12)
Viral load (log <sub>10</sub> copies/ml)	Not performed	4.60 (4.32–4.94)	Not detected	Not detected

ART, antiretroviral therapy; IQR, interquartile range.




**Fig. 1. Mucosal apoptosis, crypt epithelial proliferation, and neutrophil infiltration on colorectal biopsies by immunohistochemistry.** Mucosal biopsies demonstrate little (HIV-negative) and increased (other groups) cleaved caspase-3 staining (in red). Limited (HIV-negative, INR) and extensive (viremic, IR) colonic epithelial proliferation along the crypt base is demonstrated by Ki67 staining (in brown). Minimal (HIV-negative) versus increased neutrophil infiltration (other groups) was quantified by myeloperoxidase staining (in brown). INR, immunologic nonresponder; IR, immunologic responder.

#### **Increased mucosal apoptotic activity linked to impaired epithelial proliferation**

HIV-infected viremic untreated individuals had higher median levels of mucosal apoptosis (defined as the proportion of tissue area staining positive for caspase-3) than uninfected controls (2.9 vs. 0.1%;  $P < 0.001$ ), as did

treated subgroups ( $P \leq 0.001$ ; Fig. 2c and Table 2). ART-suppressed participants (pooling responders and non-responders) had lower median mucosal apoptosis levels than did viremic-untreated participants ( $P = 0.004$ ), but still higher levels than in uninfected controls ( $P < 0.0001$ ). Among the ART-suppressed individuals, a lower level of



**Fig. 2. Comparisons of neutrophil infiltration, epithelial proliferation, and mucosal apoptosis in colorectal biopsies from HIV-infected subgroups and HIV-uninfected controls.** (a) Neutrophil infiltration was measured by the percentage of myeloperoxidase positive staining in the rectosigmoid tissue. (b) Intestinal epithelial cell proliferation as measured by extent of Ki67 staining along colonic crypt. (c) Mucosal apoptosis was measured by percentage of cleaved caspase-3 staining in the rectosigmoid tissue. (\*) *P* values are reported first for immunologic responders with  $CD4^+ > 500$  cells/ $\mu$ l versus controls and immunologic nonresponders with  $CD4^+ < 350$  cells/ $\mu$ l versus controls.

epithelial proliferation (suggesting diminished reparative activity) was correlated with increased mucosal apoptosis ( $\rho = -0.53$ ,  $P = 0.02$ ; Fig. 3b).

### Biomarkers of immune activation and gut epithelial barrier integrity in the peripheral blood

We also compared key peripheral biomarkers of inflammation and immune activation between groups. HIV-infected viremic individuals had higher median levels of the soluble monocyte activation marker and LPS receptor, sCD14, than did controls (2.7 vs. 1.8  $\mu$ g/ml;  $P = 0.01$ ; Table 2), and this abnormality persisted in both responders and nonresponders despite the administration of effective ART. Similarly, plasma IL-6 levels (a measure of inflammation) and kynurenine/tryptophan ratio (a

measure of IDO-1 activity) were elevated in all HIV-infected groups compared to uninfected controls ( $P \leq 0.04$  for all; Table 2). Activation of the coagulation cascade, as measured by D-dimer, was modestly but not significantly elevated in viremic patients as compared to controls ( $P = 0.09$ ), and there was no evidence for a difference between controls and ART-suppressed individuals (data not shown).

### Mucosal apoptosis associated with systemic immune activation


To examine if local intestinal pathology is reflected systemically, we examined the relationship between mucosal apoptosis and peripheral biomarkers of inflammation and immune activation. In the entire cohort, levels of mucosal apoptosis were associated with plasma

**Table 2. Measures of intestinal injury, repair, and systemic immune activation.**

Measure	Control median (IQR) (n = 19)	VU median (IQR) (n = 15)	<i>P</i>	IR median (IQR) (n = 15)	<i>P</i> *	INR median (IQR) (n = 24)	<i>P</i> *
<b>Intestine</b>							
Caspase-3 (%)	0.10 (0.05–0.21)	2.94 (1.76–3.56)	<0.001	1.32 (0.84–2.41)	<0.001	0.75 (0.38–1.68)	0.001
Ki67 (%)	40.4 (31.4–42.8)	55.4 (45.2–66.6)	0.01	54.6 (52.4–62.0)	0.02	31.8 (23.8–54.3)	0.57
MPO (%)	0.28 (0.12–0.47)	0.38 (0.30–1.28)	0.04	0.44 (0.29–0.90)	0.04	0.66 (0.39–1.61)	0.001
					0.73		0.32
<b>Peripheral blood</b>							
sCD14 ( $\mu$ g/ml)	1.77 (1.54–2.34)	2.71 (2.28–4.06)	0.01	3.33 (2.33–4.19)	0.0002	3.08 (2.76–4.88)	0.0003
IL-6 (pg/ml)	1.04 (0.81–1.58)	1.59 (1.37–1.91)	0.04	1.50 (0.94–2.03)	0.10	1.54 (1.32–2.36)	0.004
K : T (nmol/l : $\mu$ mol/l)	35 (33–37)	65 (58–79)	0.0001	51 (36–60)	0.01	43 (34–49)	0.08
					0.04		0.001
D-dimer (ng/ml)	246 (207–278)	396 (243–552)	0.09	336 (220–382)	0.16	241 (198–391)	0.95
					0.31		0.18
I-FABP (pg/ml)	180 (140–276)	204 (142–250)	1.0	299 (209–407)	0.02	440 (225–658)	0.0004
					0.08		0.004

ART, antiretroviral therapy; I-FABP, intestinal fatty acid-binding protein; INR, immunologic nonresponder; IR, immunologic responder; K : T, kynurenine : tryptophan; MPO, myeloperoxidase; VU, viremic untreated. Ki67: controls (n = 17); VU (n = 8); IR (n = 14); INR (n = 15). Casp-3: controls (n = 16); VU (n = 10); IR (n = 10); INR (n = 9). MPO: controls (n = 18); VU (n = 12); IR (n = 15); INR (n = 23). sCD14/IL-6/D-dimer/I-FABP: controls (n = 17); VU (n = 8); IR (n = 14); INR (n = 15).

\**P* values are reported for comparisons to HIV-negative controls (first row) and to VU (second row).



**Fig. 3. Associations between intestinal proliferation, mucosal apoptosis, and systemic inflammation.** Intestinal epithelial proliferation is (a) positively correlated with the peripheral blood CD4<sup>+</sup> cell count in ART-suppressed individuals and (b) negatively correlated with the level of mucosal apoptosis in colorectal biopsies. Mucosal apoptosis is then linked to (c) monocyte activation as measured by soluble CD14 and (d) modestly with induction of indoleamine 2,3-dioxygenase activity as measured by the ratio of kynurenine-to-tryptophan levels in the peripheral blood.

I-FABP levels ( $\rho = 0.31$ ,  $P = 0.05$ ; Supplement A, <http://links.lww.com/QAD/A600>). Similar patterns were observed between mucosal apoptosis and IL-6 ( $\rho = 0.29$ ,  $P = 0.07$ ) and D-dimer ( $\rho = 0.22$ ,  $P = 0.17$ ); however, the relationship between apoptosis and these peripheral biomarkers did not persist within subgroups, suggesting potential confounding by HIV and ART status.

A greater level of mucosal apoptosis was positively associated with higher levels of plasma sCD14 levels ( $\rho = 0.46$ ,  $P = 0.04$ ; Fig. 3c) and kynurenine/tryptophan ratio ( $\rho = 0.42$ ,  $P = 0.08$ ; Fig. 3d) in ART-suppressed individuals. There was no evidence for a relationship between the extent of epithelial proliferation and neutrophil infiltration and systemic markers of immune activation among all patients or within any subgroup.

## Discussion

Whereas the cause of persistent immune activation during chronic HIV infection is incompletely understood, compromised barrier function and translocation of microbial products from the gut lumen into the systemic

circulation have been implicated as one potential cause [11,16,19,24,25]. In this study, we show that, similar to observations made in nonhuman primate models of SIV infection and in smaller studies of HIV-infected individuals [19,20], treated and untreated chronic HIV infection shows increased neutrophil infiltration in the gut compartment, suggesting ongoing epithelial breach. Epithelial proliferation increased in all treated and untreated individuals, except for those with impaired CD4<sup>+</sup> T-cell recovery. Consistent with the hypothesis that increased levels of mucosal apoptosis represent a response or consequence to injury, the degree of apoptosis was associated with measures of systemic microbial translocation and of innate immune activation (e.g. sCD14 and kynurenine/tryptophan ratio). Interestingly, ART-suppressed immunologic nonresponders had increased levels of apoptosis and higher levels of neutrophil infiltration, but inappropriately low epithelial proliferation, suggesting that reduced regenerative activity of the epithelium is a pathologic sequela in these individuals, as appears to also be the case for the T-cell lineage of HIV-infected individuals [26].

Whether intestinal epithelial barrier dysfunction is simply a consequence of HIV infection or a cause of innate

immune activation is unknown, and few data to date have linked the direct measures of gut epithelial barrier dysfunction to systemic markers of immune activation in this setting [17,27]. Presumably, translocating microbial products can cause systemic immune activation via activation of innate sensors including Toll-like receptors, activating myeloid lineage cells, and inducing immunoregulatory enzymes like IDO [28]. Furthermore, the kynurenine pathway of tryptophan catabolism, which may be induced both by host IDO and by gut microbes that elaborate kynurenine pathway enzymes, may contribute to Th17 and Th22 depletion in the gut-associated lymphoid tissue [29–31]. Since Th17 and Th22 cells are important in the maintenance of epithelial barrier function and clearance of translocated microbial products by coordinating the immune response (e.g. recruitment of neutrophils) [32–34], their depletion by kynurenine pathway catabolites in HIV infection may also contribute to the gut barrier dysfunction. Indeed, the kynurenine/tryptophan ratio in the peripheral blood – a marker of kynurenine pathway activity – was correlated with mucosal apoptosis in our study [28,35].

As with any retrospective cross-sectional study, there are several important limitations. First, the study participants representing the HIV subgroups are subject to selection and survival bias. In the modern era, ART is initiated earlier, and untreated and treated individuals are less likely to experience the extent of CD4<sup>+</sup> T-cell depletion and clinical progression experienced by the immunologic nonresponders. To the best of our ability, we avoided participants who were long-term nonprogressors and adjusted for nadir CD4<sup>+</sup> T cells as a measure of advanced HIV disease. Another limitation of the cross-sectional design is that we cannot determine the relative degree to which the gut epithelial barrier dysfunction is a cause or consequence of kynurenine pathway activity, but our study supports a relationship between these factors.

Interestingly, despite high mucosal apoptosis in untreated patients, myeloperoxidase staining was only modestly increased, supporting the notion that the high levels of kynurenine pathway activity observed in untreated HIV infection may impair recruitment of neutrophils [28,32]. Further attention to the relationships between mucosal immunity, the elaboration of specific cytokines that enhance epithelial homeostasis (e.g. IL-17, IL-22, and IL-6) or instigate further injury [e.g. tumor necrosis factor (TNF)- $\alpha$ , interferon (IFN)- $\gamma$ ], and their integrated effects on systemic immune activation is warranted.

Increases in epithelial proliferation, as measured by Ki67 staining, during chronic HIV infection, suggest ongoing damage and subsequent repair of the epithelial barrier, as has been demonstrated in the SIV rhesus macaque model [16]. Interestingly, the exact opposite association was observed in immunologic nonresponders; those with the greatest levels of apoptosis had the weakest epithelial

proliferative responses in spite of having the highest level of neutrophil infiltration, which is a tissue marker for gastrointestinal barrier damage. This suggests an impaired proliferative response in the immunologic nonresponders and potentially links failed homeostasis of both epithelial cells and circulating CD4<sup>+</sup> T cells. Indeed, lower epithelial Ki67 was associated with lower CD4<sup>+</sup> T-cell counts among all ART-suppressed participants. Whether dysfunction of epithelial regeneration drives poor CD4<sup>+</sup> T-cell recovery or *vice versa*, or whether common immunologic mechanisms drive both of these effects, remains unclear.

The alterations in mucosal and epithelial homeostasis described herein may explain why we and others have observed gut dysbiosis, or altered composition of the gut microbial communities, during HIV infection [31,36–39], along with expansion of the enteric virome, specifically adenovirus infections, that has been linked to epithelial pathology during pathogenic SIV infection [40]. In addition to an anatomical barrier against translocation of immunostimulatory products, the epithelial cells provide innate immune defense by secreting mucins and antimicrobial peptides, which is self-protective and may shape the microbiome, but this might possibly be impaired during HIV [41–43]. The fact that mucosal measurements did not entirely explain systemic markers of immune activation suggest that other unmeasured factors contribute to immune activation in this setting, including the mucosal microbiome or virome composition, HIV itself, and other chronic co-infections, such as cytomegalovirus. Alternatively, the relatively small sample size of this study may have limited power to detect relationships between mucosal measurements and systemic biomarkers that have high within-patient variability.

In conclusion, despite the remarkable success of ART, standard therapies do not fully restore health in the HIV-infected individuals, and persistent inflammation strongly predicts these complications. Our work suggests that elevated apoptosis and residual imbalances in epithelial homeostasis during treated HIV infection are associated with and may contribute to persistent inflammation and poor CD4<sup>+</sup> T-cell recovery. Earlier treatment may limit the abnormalities observed in the mucosal compartment and enable better CD4<sup>+</sup> T-cell recovery, but this remains to be investigated. Efforts are warranted to define the contribution of the gut epithelial barrier to microbial translocation, immune activation, and shaping of the microbial community.

## Acknowledgements

Authorship contribution: P.W.H., J.D.E., and M.S. served as the chief investigators, designed the study, and

developed the protocol and the statistical analysis plan. P.W.H. and M.S. identified the patient subgroups and tissue blocks. M.S. and J.M.I. supervised the mucosal sampling program and J.N.M. and S.G.D. provided patient samples. R.M.D., R.A., and C.D. performed the laboratory investigations, while J.M.M. and J.D.E. coordinated their implementation and interpretation. P.W.H., J.D.E., and M.S. performed the statistical analysis, generated the tables and figures, and interpreted the data. M.S. wrote the first draft of the manuscript, and all authors reviewed, revised, and approved the final manuscript.

**Funding:** This work was supported by the National Cancer Institute (K23 CA157929 to M.S.), the National Institute of Allergy and Infectious Disease (P30 AI27763), NIH grant number: R24 AI067039 and in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### Conflicts of interest

Potential conflicts of interest: Nothing to disclose.

### References

- Deeks SG, Phillips AN. **HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.** *BMJ* 2009; **338**:a3172.
- Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. **Survival of persons with and without HIV infection in Denmark, 1995–2005.** *Ann Intern Med* 2007; **146**:87–95.
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.** *Lancet* 2008; **372**:293–299.
- Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. **Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.** *PLoS One* 2013; **8**:e81355.
- Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. **Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.** *PLoS Med* 2008; **5**:e203.
- Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. **Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.** *J Infect Dis* 2010; **201**:1788–1795.
- Boulware DR, Hullsiek KH, Puroton CE, Rupert A, Baker JV, French MA, et al. **Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.** *J Infect Dis* 2011; **203**:1637–1646.
- Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, et al. **Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.** *AIDS* 2011; **25**:2123–2131.
- Hunt PW, Martin JN, Sinclair E, Brecht B, Hagos E, Lampiris H, et al. **T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.** *J Infect Dis* 2003; **187**:1534–1543.
- Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. **Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.** *J Acquir Immune Defic Syndr* 2010; **55**:316–322.
- Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. **Microbial translocation is a cause of systemic immune activation in chronic HIV infection.** *Nat Med* 2006; **12**:1365–1371.
- Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. **Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.** *J Infect Dis* 2009; **199**:1177–1185.
- Marchetti G, Bellistri GM, Borghi E, Tincati C, Ferramosca S, La Francesca M, et al. **Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy.** *AIDS* 2008; **22**:2035–2038.
- Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, Seebregts C, et al. **Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy.** *J Infect Dis* 2010; **202**:723–733.
- Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. **Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.** *J Infect Dis* 2011; **204**:1217–1226.
- Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini M, et al. **Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections.** *PLoS Pathog* 2010; **6**:e1001052.
- Li Q, Estes JD, Duan L, Jessurun J, Pambuccian S, Forster C, et al. **Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection.** *J Infect Dis* 2008; **197**:420–429.
- Kristoff J, Haret-Richter G, Ma D, Ribeiro RM, Xu C, Cornell E, et al. **Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication.** *J Clin Invest* 2014; **124**:2802–2806.
- Epple HJ, Schneider T, Troeger H, Kunkel D, Allers K, Moos V, et al. **Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients.** *Gut* 2009; **58**:220–227.
- Epple HJ, Allers K, Troger H, Kuhl A, Erben U, Fromm M, et al. **Acute HIV infection induces mucosal infiltration with CD4+ and CD8+ T cells, epithelial apoptosis, and a mucosal barrier defect.** *Gastroenterology* 2010; **139**:1289–1300.
- Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. **Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.** *J Infect Dis* 2014; **210**:1228–1238.
- Sereti I, Estes JD, Thompson WL, Morcock DR, Fischl MA, Croughs T, et al. **Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration.** *PLoS Pathog* 2014; **10**:e1003890.
- Huang Y, Louie A, Yang Q, Massenkoff N, Xu C, Hunt PW, et al. **A simple LC-MS/MS method for determination of kynurenine and tryptophan concentrations in human plasma from HIV-infected patients.** *Bioanalysis* 2013; **5**:1397–1407.
- Clarke TB, Francella N, Huegel A, Weiser JN. **Invasive bacterial pathogens exploit TLR-mediated downregulation of tight junction components to facilitate translocation across the epithelium.** *Cell Host Microbe* 2011; **9**:404–414.
- Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, et al. **Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation.** *PLoS Pathog* 2010; **6**:e1000852.
- McCune JM. **The dynamics of CD4+ T-cell depletion in HIV disease.** *Nature* 2001; **410**:974–979.
- Dunham RM, Vujkovic-Cvijin I, Yukl SA, Broadhurst MJ, Loke P, Albright RG, et al. **Discordance between peripheral and colonic markers of inflammation during suppressive ART.** *J Acquir Immune Defic Syndr* 2014; **65**:133–141.
- Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, et al. **Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 regulatory T cells in HIV disease.** *Sci Transl Med* 2010; **2**:32ra36.

29. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, *et al.* **Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections.** *Blood* 2008; **112**:2826–2835.
30. Favre D, Mold J, Hunt PW, Kanwar K, Loke P, Seu L, *et al.* **Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease.** *Sci Transl Med* 2010; **2**:32ra36.
31. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, *et al.* **Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism.** *Sci Transl Med* 2013; **5**:193ra191.
32. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, *et al.* **Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut.** *Nat Med* 2008; **14**:421–428.
33. Klatt NR, Harris LD, Vinton CL, Sung H, Briant JA, Tabb B, *et al.* **Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection.** *Mucosal Immunol* 2010; **3**:387–398.
34. Kim CJ, Nazli A, Rojas OL, Chege D, Alidina Z, Huibner S, *et al.* **A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis.** *Mucosal Immunol* 2012; **5**:670–680.
35. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, *et al.* **Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection.** *PLoS Pathog* 2009; **5**:e1000295.
36. Mutlu EA, Keshavarzian A, Losurdo J, Swanson G, Siewe B, Forsyth C, *et al.* **A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects.** *PLoS Pathog* 2014; **10**:e1003829.
37. Dillon SM, Lee EJ, Kotter CV, Austin GL, Dong Z, Hecht DK, *et al.* **An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia.** *Mucosal Immunol* 2014; **7**:983–994.
38. McHardy IH, Li X, Tong M, Ruegger P, Jacobs J, Borneman J, *et al.* **HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota.** *Microbiome* 2013; **1**:26.
39. Lozupone CA, Li M, Campbell TB, Flores SC, Linderman D, Gebert MJ, *et al.* **Alterations in the gut microbiota associated with HIV-1 infection.** *Cell Host Microbe* 2013; **14**:329–339.
40. Handley SA, Thackray LB, Zhao G, Presti R, Miller AD, Droit L, *et al.* **Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome.** *Cell* 2012; **151**:253–266.
41. Sheng YH, Lourie R, Linden SK, Jeffery PL, Roche D, Tran TV, *et al.* **The MUC13 cell-surface mucin protects against intestinal inflammation by inhibiting epithelial cell apoptosis.** *Gut* 2011; **60**:1661–1670.
42. George MD, Sankaran S, Reay E, Gelli AC, Dandekar S. **High-throughput gene expression profiling indicates dysregulation of intestinal cell cycle mediators and growth factors during primary simian immunodeficiency virus infection.** *Virology* 2003; **312**:84–94.
43. Sankaran S, George MD, Reay E, Guadalupe M, Flamm J, Prindiville T, *et al.* **Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration.** *J Virol* 2008; **82**:538–545.